This educational activity was recorded during a continuing medical education (CME) plenary session at the American College of Osteopathic Family Physicians Annual Convention & Scientific Seminars (ACOFP '13) on March 23, 2013, in Las Vegas, Nevada.
New treatment recommendations from the American Diabetes Association encourage an individualized, patient-centered approach in the management of type 2 diabetes mellitus (T2DM). Osteopathic family physicians who manage patients with T2DM need to be aware of changes in the standard of care for this increasingly common disease. Moreover, the number of agents available to treat T2DM has increased significantly in recent years, resulting in greater flexibility—and greater uncertainty—when selecting appropriate treatment options for particular patients. Specifically, the injectable agents for T2DM—insulin and the glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—have differing glycemic and nonglycemic effects that are important to distinguish for appropriate individualization of therapy. This activity will provide a succinct overview of the application of the new guidelines and the use of insulin and GLP-1 RAs in T2DM.